| efavirenz / Generic mfg. |
| Recruiting | 4 | 50 | | Efavirenz 400mg orally daily versus 600mg orally daily, in combination with other anti-retrovirals, 4 months | School of Pharmacy, Chinese University of Hong Kong; Dr Leung Wai Shing, Take on all the responsibilities of sponsorship jointly with the primary sponsor, The Chinese University of Hong Kong | HIV infection | | | | |
2005-004021-26: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. |
|
|
| Completed | 4 | 60 | Europe | Efavirenz, AZT/3TC, emtricitabine/tenofovir, Capsule*, Tablet, Film-coated tablet, SUSTIVA, COMBIVIR, TRUVADA | University Hospital Birmingham | HIV | | | | |
2011-004935-30: Study “before-after”: Adherence Evaluation to antiretroviral therapy administered in two different ways Studio ''before-after'' di valutazione dell'aderenza di due diverse modalita' di somministrazione della terapia antiretrovirale |
|
|
| Ongoing | 4 | 400 | Europe | Film-coated tablet, EPIVIR*FL 30CPR RIV 300MG, VIREAD*30CPR 245MG, ZIAGEN*6BLISTER 10CPR 300MG, SUSTIVA*30CPR RIV 600MG BLIST, RETROVIR*60CPR 300MG, TRUVADA*30CPR RIV 200MG/245MG, KIVEXA*BL 30CPR RIV 600MG+300M, COMBIVIR*60CPR RIV 150MG+300MG, ATRIPLA*30CPR RIV600+200+245MG | U.L.S.S. 9 DI TREVISO, studio no profit, farmaci a carico del SSN | HIV infection Infezione da HIV, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2011-005581-37: Efficacy of Switching to Lopinavir/Ritonavir (Kaletra) in Improving Cognitive function in patients treated with Efavirenz (EFV) (SLICE Study) |
|
|
| Completed | 4 | 30 | Europe | Kaletra, Film-coated tablet, Kaletra | The Newcastle upon Tyne Hospitals NHS Foundation Trust, AbbVie Limited | Cognitive function and sleep pattern in HIV-1 patients, HIV-1 infection, Diseases [C] - Immune System Diseases [C20] | | | | |
2015-003278-34: A RANDOMIZED BIOEQUIVALENCE STUDY OF EFAVIRENZ GENERIC DRUG AND SUSTIVA® (TABLETS 600 mg) IN PATIENTS WITH HIV-1 STUDIO RANDOMIZZATO PER LA VALUTAZIONE DELLA BIOEQUIVALENZA TRA EFAVIRENZ GENERICO E SUSTIVA® ENTRAMBI IN COMPRESSE DA 600 MG IN PAZIENTI CON HIV-1 |
|
|
| Terminated | 4 | 40 | Europe | Efavirenz, SUSTIVA, non applicabile, Film-coated tablet, EFAVIRENZ MYLAN - 600 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PVDC/AL, SUSTIVA - 600 MG COMPRESSE FILM RIVESTITE 30 COMPRESSE IN BLISTER USO ORALE | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Mylan S.p.A. | Patients with HIV-1 Pazienti affetti da HIV-1, Patients with HIV-1 Pazienti affetti da HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
2005-003243-31: Randomized, double-blind, study to compare the incidence and intensity lf neurologic and pschiatic adverse events of efavirenz when given as a stepped dosage (200 mg qd for 6 days, 400 mg qd for 7 days and 600 mg qd from the day 14 farward) with the usual dosage (600 mg qd from first day) |
|
|
| Ongoing | 4 | 100 | Europe | EFAVIRENZ, sustiva, sustiva | Luis Fernando López Cortés | Pacientes infectados por el VIH a los que su medico responsable les haya prescrito efavirez como parte de su tratamiento antiretroviral | | | | |
2008-006371-67: EFFECT OF THIENOPYRIDINE DERIVATIVE (CLOPIDOGREL) ON THE DISPOSITION OF EFAVIRENZ AND NEVIRAPINE IN HIV POSITIVE PATIENTS |
|
|
| Ongoing | 4 | 37 | Europe | plavix, Nevirapine, Efavirenz, B01AC04, J05AG03, Plavix (Sanofi Synthelabo, Guildford, United Kingdom), viramune, sustiva;stocrin, Plavix (Sanofi Synthelabo, Guildford, United Kingdom), viramune, sustiva;stocrin | Royal Liverpool and Broadgreen University Hospital, University of Liverpool | To determine whether anti-platelet agent clopidigrel influences the disposition of NNRTIs (efavirenz and nevirapine) | | | | |
2009-014694-40: A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy |
|
|
| Ongoing | 4 | 12 | Europe | | | HIV | | | | |
2012-003595-39: A clinical trial to compare brain function and neurocognitive performance in antiretroviral treatments with different levels of penetration in the central nervous system. Ensayo clínico para comparar el funcionamiento cerebral y rendimiento neurocognitivo en tratamientos antirretrovirales con distintos niveles de penetracion en el sistema nervioso central. |
|
|
| Ongoing | 4 | 40 | Europe | ATAZANAVIR, Tablet, Capsule, hard, Reyataz, Norvir, Kivexa, Sustiva, Truvada | Fundación para la Investigación Biomédica del Hospital Universitario La Paz, Fundacion para la Investigacion Biomédica del Hospital Universitario La Paz | Patients infected with human immunodeficiency virus who have never received antiretroviral treatment. Pacientes infectados con virus de inmunodeficiencia humana que nunca han recibido tratamiento antirretroviral., HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003325-41: PREemptive Pharmacogenomic testing for Preventing Adverse drug REactions (PREPARE) |
|
|
| Completed | 4 | 450 | Europe | Syrup, Tablet, Capsule, hard, Powder for injection, Capsule, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Codeine, Acenocoumarol, Amitriptyline, Aripiprazole, Atomoxetine, Atorvastatine, Azathioprine, Capecitabine, Carbamazepine, Citalopram, Clomipramine, Clopidogrel, Clozapine, Efavirenz, Escitalopram, Flecainide, Flucloxacillin, Fluorouracil, Haloperidol, Irinotecan, Mercaptopurine, Metoprolol, Oxycodone, Paroxetine, Phenprocoumon, Phenytoin, ORAP 1 mg Tabletten, Propafenone, Sertraline, Simvastatin, Tacrolimus, Tamoxifen, Tegafur, Tioguanine, Tramadol, Venlafaxine, Voriconazole, Zuclopenthixol, Ethinylestradiol, ORAP 4 mg Tabletten | Leiden University Medical Center, Leiden University Medical Center | Adverse drug reactions, Side-effects, Not possible to specify | | | | |
ChiCTR1900020750: A prospective, randomized, non-inferior clinical trial for antiviral therapy optimization programs for AIDS patients |
|
|
| Not yet recruiting | 4 | 200 | | Zidovudine 300mg twice daily / tenofovir 300mg once daily + lamivudine 300mg once daily + nevirapine 200mg twice daily / efavirenz 600mg once daily ;Lopinavir/ritonavir 500mg twice daily + lamivudine 300mg once daily | The Fifth Affilated Hosipital Of Sun Yat-sen University; The Fifth Affiliated Hosipital Of Sun Yat-sen University, Hospital funding and self-finacing | AIDS | | | | |
NCT04296695: Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection |
|
|
| Active, not recruiting | 4 | 250 | RoW | B/F/TAF, Biktarvy, TDF/3TC/EFV, Tenofovir /Ravmidine /Efavirenz | Peking Union Medical College Hospital, Gilead Sciences | HIV-1-infection | 12/22 | 12/23 | | |
| Completed | 4 | 7 | US | Efavirenz 600mg | Washington University School of Medicine | HIV | 12/24 | 12/24 | | |
ChiCTR2200062461: Preliminary Evaluation of the Safety and Efficacy of the Antiretroviral Regimen of 2 NRTIs Drugs Combined with Albuvirtide in the Treatment of HIV/AIDS Patients with Tuberculosis Infection |
|
|
| Not yet recruiting | 4 | 30 | | 2 NRTIS combined with Albuvirtide ;2 NRTIS combined with Efavirenz (EFV) | The Second Affiliated Hospital of Southern University of Science and Technology (The Third People's Hospital of Shenzhen); The Second Affiliated Hospital of Southern University of Science and TechnologyThe Third People's Hospital of Shenzhen), Frontier Biotechnologies Inc | HIV-1 | | | | |
| Recruiting | 4 | 888 | RoW | Artemether-lumefantrine, Efavirenz, Dolutegravir | Makerere University | HIV Coinfection, Malaria | 01/24 | 03/24 | | |
103900, 2024-515487-31-00: Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) |
|
|
| Completed | 4 | 163 | Europe | Ziagen 300 mg film-coated tablets, INTELENCE 200 mg tablets, Eviplera 200 mg/25 mg/245 mg film-coated tablets, EDURANT 25 mg film-coated tablets, Telzir 700 mg film-coated tablets, TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets, Delstrigo 100 mg/300 mg/245 mg film-coated tablets, Norvir 100 mg film-coated tablets, Ritonavir Accord 100 mg filmomhulde tabletten, Descovy 200 mg/10 mg film-coated tablets, REYATAZ?300?mg hard capsules, REKAMBYS 600 mg prolonged-release suspension for injection, Tivicay 50 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Viread 245 mg film-coated tablets, Emtriva 200 mg hard capsules, Descovy 200 mg/25 mg film-coated tablets, CELSENTRI 300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Odefsey 200 mg/25 mg/25 mg film-coated tablets, STOCRIN 600 mg film-coated tablets, Vocabria 400 mg prolonged-release suspension for injection, INTELENCE 100 mg tablets, Aptivus 250?mg soft capsules, Pifeltro 100 mg film-coated tablets, CELSENTRI 150 mg film-coated tablets, Kivexa 600 mg/300 mg film-coated tablets, ISENTRESS 400 mg film-coated tablets, Fuzeon 90 mg/ml powder and solvent for solution for injection, Vocabria 600 mg prolonged-release suspension for injection, ISENTRESS 600 mg film-coated tablets | Stichting Radboud universitair medisch centrum | HIV-infected | | | | |
ChiCTR2500113428: Study on the Effect of Antiretroviral Therapy Centered on Enovirine on PD-1 Expression of CD8+ T Cells Induced by Cholesterol |
|
|
| Completed | 4 | 150 | | Switching from efavirenz to enovirine for antiviral therapy; Use efavirenz | Xixi Hospital of Hangzhou; Xixi Hospital of Hangzhou, The Hangzhou Biomedical Industry Support Project(grant number 2023WJC037). | HIV | | | | |
2006-001208-35: A multicentre, randomised study comparing the starting treatment with full dose or dose escalation of nevirapine in patients needing efavirenz withdrawal due to adverse reactions. Estudio multicéntrico aleatorizado para comparar el inicio del tratamiento con Neviparina a dosis plenas o a dosis escaladas en pacientes que precisan la retirada de Efavirenz por reacciones adversas |
|
|
| Ongoing | 3/4 | 80 | Europe | Viramune ®, Viramune ®, Viramune ® | Esteban Ribera Pascuet | HIV infection | | | | |
2006-004476-12: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. |
|
|
| Ongoing | 3/4 | 80 | Europe | Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine, Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine, Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine | University of New South Wales | Chronic HIV infection | | | | |
2004-000441-38: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study) |
|
|
| | 3/4 | 2 | Europe | NA, NA, INVIRASE*270 CPS 200 MG, NORVIR*336 CPS MOLLI 100 MG, CRIXIVAN*180 CPS 400 MG, VIRACEPT*270 CPR 250 MG, FORTOVASE*180 CPS 200 MG, AGENERASE*240 CPS 150 MG, KALETRA*180 CPS BLISTER, VIRAMUNE*60 CPR 200 MG, SUSTIVA*90 CPS 200 MG, RETROVIR* 28 CPR 300 MG, VIDEX 400*30 CPS 400 MG, HIVID 0,750*100 CPR 0,750 MG, ZERIT 40*56 CPS 40 MG, EPIVIR*60 CPR 150 MG, COMBIVIR*60CPR BL 150/300MG, ZIAGEN*60 CPR RIV. 300 MG, TRIZIVIR*60 CPR RIV. BLISTER, VIREAD*30 CPR 245 MG, FUZEON*90MG/ML 60FL+60FL+60S | National Institute of Allergy and Infectious Diseases, National Institutes of Health, COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDS | HIV infection | | | | |
Encore1 intensive PK sub-study, ACTRN12612000263897: A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus 2N(t)RTI in antiretroviral-naive HIV-infected individuals over 96 weeks. Encore1 intensive pharmacokinetics sub-study |
|
|
| Active, not recruiting | 3 | 40 | | | Kirby Institute/University of New South Wales | HIV infection | | | | |
The Neurocoginitive sub study of Encore1, ACTRN12612000622808: The Neurocognitive Sub Study of Encore1:A Randomised, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus 2N(t)RTI in Antiretroviral-naive HIV-Infected Individuals Over 96 Weeks |
|
|
| Active, not recruiting | 3 | 124 | | | Kirby Institute, Univeristy of New South Wales | HIV | | | | |
Encore1, ACTRN12610001097033: A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase inhibitors (N(t)RTI) in antiretroviral-naïve Human Immunodeficiency virus (HIV)-infected individuals over 96 weeks. |
|
|
| Active, not recruiting | 3 | 630 | | | National Centre for HIV Epidemiology and Clinical Research, University of New South Wales | HIV infection | | | | |
2014-003419-12: Switch from Efavirenz/Atripla to Rilpivirine Switch da Efavirenz/Atripla a Rilpivirina |
|
|
| Terminated | 3 | 90 | Europe | EVIPLERA, ATRIPLA, Capsule, hard, EVIPLERA, ATRIPLA | AZIENDA OSPEDALIERA SAN GERARDO, MONZA, ITALIA, Gilead Sciences Srl | HIV INFECTION INFEZIONE DA HIV, HIV HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2010-018878-21: A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to raltegravir |
|
|
| Ongoing | 3 | 40 | Europe | Isentress, Truvada (tenofovir disoproxil/emtricitabine), Isentress, Truvada, Isentress, Truvada | St Stephen\'s AIDS Trust | HIV | | | | |
2016-002413-22: Open label, Randomized clinical trial to evaluate switching from dual regimens to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients Studio in aperto, randomizzato, per valutare il passaggio da una terapia duplice ad una terapia con E/C/F/TAF in pazienti adulti HIV positivi con carica virale negativa. |
|
|
| Terminated | 3 | 100 | Europe | Tivicay (dolutegravir), Emtriva, Lamivudina, Viread, Ziagen, Edurant, Intelence, Sustiva, Viramune, Film-coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Genvoya¿ 150 mg/150mg/200mg/10mg, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EMTRIVA - 30 CAPSULE RIGIDE IN BLISTER DA 200 MG, LAMIVUDINA MYLAN - 300 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PVDC/AL, VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE, ZIAGEN - 300 MG COMPRESSE FILMRIVESTITE 6 BLISTER 10 COMPRESSE USO ORALE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE, SUSTIVA - 600 MG COMPRESSE FILM RIVESTITE 1 FLACONE 30 COMPRESSE USO ORALE, VIRAMUNE - 400 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - BLISTER (PVC/AL) 30 COMPRESSE | OSPEDALE SAN RAFFAELE, Gilead Sciences Inc. | HIV infection Infezione da HIV, HIV infected subjects pazienti affetti da virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04303598: Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients |
|
|
| Not yet recruiting | 3 | 720 | RoW | FNC, Azvudine, 3TC, Lamivudine, TDF, Tenofovir Fumarate, EFV, Efavirenz, FNC placebo, Azvudine placebo, 3TC placebo, Lamivudine placebo | HeNan Sincere Biotech Co., Ltd | HIV-infection/Aids | 05/22 | 08/22 | | |
EDOSE, NCT04513379: Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients |
|
|
| Not yet recruiting | 3 | 80 | NA | Efavirenz 600mg, Efavirenz 400mg | Shanghai Public Health Clinical Center | HIV Infections, Tuberculosis | 10/22 | 01/23 | | |
ADORE, NCT04429152: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance |
|
|
| Recruiting | 3 | 25 | RoW | Doravirine/Lamivudine/Tenofovir, Delstrigo | Professor Francois Venter | HIV-1-infection | 09/23 | 09/23 | | |
NCT07482085: Efavirenz for the Treatment of Creutzfeldt-Jakob Disease |
|
|
| Not yet recruiting | 3 | 246 | RoW | Efavirenz, Placebo | Xuanwu Hospital, Beijing | Creutzfeldt-Jakob Disease | 12/28 | 12/28 | | |
| Not yet recruiting | 2 | 48 | | | The University of Newcastle, Hunter Medical Research Institute | high-grade serous ovarian cancer, high-grade serous fallopian tube carcinoma, primary peritoneal carcinoma | | | | |
2007-003896-38: PHARMACOKINETICS AND PHARMACODYNAMICS IN THE OPTIMIZATION OF ANTIRETROVIRAL TREATMENT. |
|
|
| Ongoing | 2 | 50 | Europe | Capsule, soft, Capsule, hard, Coated tablet, Tablet, KALETRA, REYATAZ, TELZIR, VIRAMUNE, SUSTIVA | AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA | Children 2-16 years old with documented vertical HIV-1 infection | | | | |
2008-004970-41: Phase II open-label randomized multicenter trial to compare the efficacy and safety of two different doses of raltegravir and efavirenz, all in combination with tenofovir and lamivudine, in naive HIV-1-infected patients receiving rifampin for active tuberculosis. |
|
|
| Ongoing | 2 | 15 | Europe | Sustiva, Viread, Epivir, MK-0518, BMS-561525, raltegravir, Sustiva, Viread, Epivir, Isentress, Sustiva, Viread, Epivir, Isentress | Agence nationale de recherches sur le sida et les hépatites virales. ANRS. | HIV-1 Infection and tuberculosis | | | | |
2019-004498-18: Clinical trial to test efficacy and safety of efavirenz in patients with Niemann-Pick C disorder with cognitive impairment Ensayo Clínico para evaluar la eficàcia y Seguridad del efavirenz en pacientes con la enfermedad de Niemann pick tipo C con deterioro cognitivo |
|
|
| Ongoing | 2 | 11 | Europe | Efavirenz, Capsule, SUSTIVA efavirenz 100 mg | Dr. Jordi Gascón / Dra. Lola Ledesma, Fundación Española Niemann-Pick | Niemann Pick tipo C (NPC) Niemann Pick C type (NPC), Niemann Pick C type (NPC) is a genetic neurological disorder. Niemann Pick tipo C (NPC) es una patología genética neurodegenerativa., Body processes [G] - Genetic Phenomena [G05] | | | | |
NCT03282799: Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women |
|
|
| Completed | 2 | 72 | RoW | etonogestrel implant, Nexplanon, Implanon | Catherine Anne Chappell, Infectious Disease Institute, Kampala, Uganda, University of Nebraska | HIV/AIDS, Contraception | 12/20 | 10/22 | | |
| Recruiting | 2 | 80 | RoW | Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz, SHR-A1811, SHR-A2102, SHR-1316, Mecapegfilgrastim, AK131, Theophylline | Fudan University | Triple-negative Breast Cancer | 12/26 | 03/27 | | |
HUB-NEU-2023-01, 2023-505832-36-01: OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADULT OR LATE-ONSET JUVENILE TYPE C NIEMANN-PICK DISEASE WITH COGNITIVE IMPAIRMENT |
|
|
| Active, not recruiting | 1/2 | 16 | Europe | EFAVIRENZ
| Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL, Fundaci?n Niemann-Pick Espa | Type C Niemann-Pick Disease | | | | |
2023-509613-37-01: A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Efavirenz in Patients with Early Alzheimer?s Disease |
|
|
| Recruiting | 1/2 | 40 | Europe | Placebo Efavirenz tablets, EFAVIRENZ | Amsterdam UMC | Alzheimer's Disease | | | | |
NCT04680091: Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer |
|
|
| Active, not recruiting | 1 | 20 | RoW | Pyrotinib Maleate, Efavirenz | Jiangsu HengRui Medicine Co., Ltd. | Healthy Subjects, Drug-drug Interaction, Pyrotinib | 01/21 | 12/21 | | |
NCT05141422: A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers |
|
|
| Active, not recruiting | 1 | 20 | RoW | SHR2150 tablet、efavirenz | Jiangsu HengRui Medicine Co., Ltd. | Human Immunodeficiency Virus Infection | 01/22 | 01/22 | | |
| Completed | 1 | 16 | US | Nemtabrutinib, MK-1026, ARQ 531, Efavirenz | Merck Sharp & Dohme LLC | Healthy | 10/23 | 10/23 | | |
NCT05909644: An Open-label DDI Study of Omaveloxolone in Healthy Subjects |
|
|
| Completed | 1 | 20 | US | Omaveloxolone, RTA 408, Efavirenz | Biogen, Celerion, Q2 Solutions, Altasciences Company Inc. | Healthy Adult Subjects | 08/23 | 08/23 | | |
NCT05995249: A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults |
|
|
| Completed | 1 | 172 | US | TAK-279, Erythromycin, Phenytoin, Efavirenz | Takeda | Healthy Volunteers | 12/23 | 12/23 | | |
| Completed | 1 | 34 | RoW | Itraconazole+TGRX-326, Efavirenz+TGRX-326 | Shenzhen TargetRx, Inc., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Non Small Cell Lung Cancer | 05/24 | 05/24 | | |
NCT06797674: A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) |
|
|
| Completed | 1 | 34 | US | MK-7602, Efavirenz, MK-0831 | Merck Sharp & Dohme LLC | Healthy | 08/25 | 08/25 | | |
| Completed | 1 | 38 | US | Mavorixafor, Carbamazepine, Efavirenz | X4 Pharmaceuticals | Healthy Participants | 05/25 | 05/25 | | |
ChiCTR2300074601: A multicenter Cohort study of 48-week safety and efficacy of ainuovirine-containing regimen versus bictegravir-containing and efavirenz-containing regimens in treatment-naive HIV-1-infected patients |
|
|
| Not yet recruiting | 1 | 665 | | Medication and examination according to the treatment plan, without any additional preventive measures; Medication and examination according to the treatment plan, without any additional preventive measures; Medication and examination according to the treatment plan, without any additional preventive measures | The Third People's Hospital of Shenzhen; The Third People's Hospital of Shenzhen, Jiangsu Aidi Pharmaceutical Co., LTD | HIV infection | | | | |
NCT05789173: Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK |
|
|
| Recruiting | 1 | 60 | US | Methadone and Tizanidine, Efavirenz, Methadone and Tizanidine | Indiana University, National Institute of General Medical Sciences (NIGMS) | Drug-Drug Interaction | 04/26 | 04/26 | | |
NCT07341672: A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants |
|
|
| Not yet recruiting | 1 | 80 | RoW | Clifutinib, Itraconazole, fluconazole, efavirenz | Sunshine Lake Pharma Co., Ltd. | Healthy Adult Subject | 04/27 | 05/27 | | |
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection |
|
|
| No Longer Available | N/A | | US | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada |
|
|
| No Longer Available | N/A | | Canada | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
ChiCTR1900024611: Dual therapy with lopinavir/ritonavir plus lamivudine could be an effective alternative for antiretroviral-therapy-naive adults with HIV-1 infection in resource-limited settings: planned 144 week, a randomized, open-label and non-inferiority study from China |
|
|
| Recruiting | N/A | 200 | | Dual-therapy of lopinavir/ritonavir (LPV/r) plus 3TC (DT group) ;triple-therapy regimen containing tenofovir (TDF), 3TC plus efavirenz (EFV) | Guangzhou Eighth People's Hospital; Level of the institution：, no | AIDS | | | | |
| Recruiting | N/A | 26 | Canada | Efavirenz 600mg, Sustiva, Teva-Efavirenz, Mylan-Efavirenz, Jamp-Efavirenz, Auro-Efavirenz | University of Toronto, Ontario HIV Treatment Network, Maple Leaf Research, Unity Health Toronto | Hiv | 11/27 | 11/28 | | |
ChiCTR2500113922: A cohort study of efficacy, safety, and adherence of regimen containing efavirenz versus regimen containing efavirenz in HIV-1-positive initial treatment |
|
|
| Recruiting | N/A | 270 | | None; None | Chest Hospital of Guangxi Zhuang Autonomous Region; Chest Hospital of Guangxi Zhuang Autonomous Region, Jiangsu Aidi Pharmaceutical Co., Ltd | HIV infection | | | | |
ChiCTR2300078465: Real world data study on the impact of low-dose efavirenz to ainuovirine on the related quality of life of AIDS patients |
|
|
| Recruiting | N/A | 200 | | None | The First People's Hospital of Linping District, Hangzhou; The First People's Hospital of Linping District, Hangzhou | HIV | | | | |
NCT00476606: A Prospective Cohort of Children With HIV Infection |
|
|
| Completed | N/A | 500 | RoW | Zidovudine, Stavudine, Didanosine, Lamivudine, Nevirapine, Efavirenz, LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir | The HIV Netherlands Australia Thailand Research Collaboration, Khon Kaen University | HIV Infections | 09/24 | 09/24 | | |
